PMID- 29889596
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 30
IP  - 3
DP  - 2019 May
TI  - Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: 
      does it work?
PG  - 258-263
LID - 10.1080/09546634.2018.1487525 [doi]
AB  - BACKGROUND: Retinoids exert their biologic effects by binding to intracellular 
      retinoic-acid receptors (RARs) and/or retinoid X receptors (RXRs). Early-stage 
      mycosis fungoides (MF) has been effectively treated with bexarotene, an 
      RXR-agonist, with overall response (OR) rates 54-67% and complete response (CR) 
      rates 7-27%. Data on RAR-agonist monotherapy are limited. OBJECTIVE: To analyze 
      the effectiveness of RAR-agonist monotherapy for early-stage MF. METHODS: Data on 
      patients with early-stage MF treated with acitretin/isotretinoin monotherapy at a 
      tertiary cutaneous lymphoma clinic in 2010-2017 were collected retrospectively 
      from the medical files. RESULTS: Thirty-five patients (26 males) of median age 50 
      years (range 8-83) with early-stage MF (IA 9, IB 26) underwent 37 treatment 
      events: 25 acitretin and 12 isotretinoin at a median dosages of 0.3 mg/kg (range 
      0.2-0.9) and 0.2 mg/kg (range 0.1-0.7), respectively. Median time to maximal 
      response was 6 months for both (range 1-10 for acitretin, 3-16 for isotretinoin); 
      median treatment duration was 10 months (range 3-46) for acitretin, and 9 months 
      (range 3-55) for isotretinoin. OR was 64% for acitretin and 80% for isotretinoin, 
      and CR, 4% and 8%, respectively. Side-effect profiles were as previously reported 
      for retinoids. CONCLUSIONS: Early-stage MF patients may benefit from low dose 
      RAR-agonist monotherapy, although the CR rate is low.
FAU - Amitay-Laish, Iris
AU  - Amitay-Laish I
AD  - a Department of Dermatology , Rabin Medical Center, Beilinson Hospital , Petach 
      Tikva, Israel.
AD  - b Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel.
FAU - Reiter, Ofer
AU  - Reiter O
AD  - a Department of Dermatology , Rabin Medical Center, Beilinson Hospital , Petach 
      Tikva, Israel.
AD  - b Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel.
FAU - Prag-Naveh, Hadas
AU  - Prag-Naveh H
AD  - a Department of Dermatology , Rabin Medical Center, Beilinson Hospital , Petach 
      Tikva, Israel.
FAU - Kershenovich, Ruben
AU  - Kershenovich R
AD  - a Department of Dermatology , Rabin Medical Center, Beilinson Hospital , Petach 
      Tikva, Israel.
FAU - Hodak, Emmilia
AU  - Hodak E
AD  - a Department of Dermatology , Rabin Medical Center, Beilinson Hospital , Petach 
      Tikva, Israel.
AD  - b Sackler Faculty of Medicine , Tel Aviv University , Tel Aviv , Israel.
LA  - eng
PT  - Journal Article
DEP - 20180730
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Dermatologic Agents)
RN  - 0 (Retinoid X Receptors)
RN  - EH28UP18IF (Isotretinoin)
RN  - LCH760E9T7 (Acitretin)
SB  - IM
MH  - Acitretin/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Dermatologic Agents/*therapeutic use
MH  - Female
MH  - Humans
MH  - Isotretinoin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Mycosis Fungoides/*drug therapy
MH  - Retinoid X Receptors/agonists
MH  - Retrospective Studies
MH  - Skin Neoplasms/*drug therapy
MH  - Young Adult
OTO - NOTNLM
OT  - Acitretin
OT  - RAR
OT  - early-stage mycosis fungoides
OT  - isotretinoin
OT  - retinoic acid receptor
OT  - retinoids
EDAT- 2018/06/12 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/06/12 06:00
PHST- 2018/06/12 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/06/12 06:00 [entrez]
AID - 10.1080/09546634.2018.1487525 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2019 May;30(3):258-263. doi: 10.1080/09546634.2018.1487525. 
      Epub 2018 Jul 30.